

Application No. 10/589,687

Filed: August 17, 2006

TC Art Unit: 1647

Confirmation No.: 9909

**RECEIVED**  
**CENTRAL FAX CENTER**  
**MAY 21 2008**AMENDMENT TO THE CLAIMS

1. (Currently Amended) A method of determining the state of a disease or condition associated with endothelial cell dysfunction in a subject, the method comprising:

providing a subject suffering from or thought to be at risk of suffering from a disease or condition associated with endothelial cell dysfunction;

determining a level of profilin-1 at a site in the subject; and

relating an elevated level of profilin-1 ~~the level~~ to the state of the disease or condition of the subject.

2. (Original) The method of claim 1, wherein an increased level of profilin-1 indicates a positive diagnosis for the disease or condition.

3. (Original) The method of claim 1, wherein the disease or condition is diabetic vascular disease.

4. (Original) The method of claim 1, wherein the disease or condition is atherosclerosis.

5. (Original) The method of claim 1, wherein the disease or condition is a vascular disease selected from the group consisting of peripheral vascular disease, cerebrovascular disease, cardiovascular disease and any combination thereof.

6. (Original) The method of claim 1, wherein the site is associated with a vascular sample from the subject.

-2-

WRINGARTEN, SCHURGIN,  
GAGNEBIN & LEBOVICI LLP  
TEL. (617) 542-2290  
FAX. (617) 491-0313

Application No. 10/589,687  
Filed: August 17, 2006  
TC Art Unit: 1647  
Confirmation No.: 9909

7. (Original) The method of claim 6, wherein the vascular sample is a serum sample.
8. (Original) The method of claim 6, wherein the vascular sample is a plasma sample.
9. (Original) The method of claim 1, wherein the site is associated with a tissue sample from the subject.
10. (Original) The method of claim 9, wherein the tissue sample from the subject is an aorta tissue sample.
11. (Original) The method of claim 9, wherein the tissue sample from the subject is a retina tissue sample.
12. (Original) A kit for performing the method of determining the state of a disease or condition associated with endothelial cell dysfunction in claim 1, the kit comprising:
  - an indicator, wherein the indicator is capable of indicating the increased level of profilin-1; and
  - a device, wherein the device is capable of qualitatively or quantitatively monitoring the indicator for indication of the increased level of profilin-1.
13. (Original) A method for prophylaxis or treatment of a disease or condition associated with endothelial cell dysfunction in a subject, the method comprising:
  - providing a subject suffering from or thought to be at risk of suffering from a disease or condition associated with endothelial cell dysfunction;
  - administering to the subject a therapeutic composition or protocol to inhibit an activity or function of profilin-1,

-3-

WEINMARTEN, SCHURGIN,  
CAGNERIN & LEROVICKI LLP  
TEL. (617) 542-2290  
FAX. (617) 431-0313

Application No. 10/589,687  
Filed: August 17, 2006  
TC Art Unit: 1647  
Confirmation No.: 9909

wherein inhibiting the activity or function of profilin-1 prevents or treats the disease or condition.

14. (Original) The method of claim 13, wherein a pharmaceutically acceptable carrier comprises the therapeutic composition.

15. (Original) The method of claim 13, wherein the therapeutic protocol comprises modifying, substituting, regulating or interfering with a gene associated with profilin-1 activity or function.

16. (Original) The method of claim 13, wherein the therapeutic protocol comprises downregulating gene transcription associated with profilin-1 synthesis.

17. (Original) The method of claim 13, wherein the disease or condition is diabetic vascular disease.

18. (Original) The method of claim 13, wherein the disease or condition is atherosclerosis.

19. (Original) The method of claim 13, wherein the disease or condition is a vascular disease selected from the group consisting of cerebrovascular disease, cardiovascular disease, peripheral vascular disease and any combination thereof.

20. (Original) A therapeutic composition for prophylaxis or treatment of a disease or condition associated with endothelial cell dysfunction in a subject, the therapeutic composition comprising:

-4-

WEINGARTEN, SCHURIN,  
CAGNESIN & LEBOVICI LLP  
TEL. (617) 542-2290  
FAX. (617) 451-0313

Application No. 10/589,687  
Filed: August 17, 2006  
TC Art Unit: 1647  
Confirmation No.: 9909

a inhibitor capable of inhibiting an activity or function of profilin-1; and

a pharmaceutically acceptable carrier comprising the inhibitor.

21. (Original) The therapeutic composition of claim 20, wherein the disease or condition is diabetic vascular disease.

22. (Original) The therapeutic composition of claim 20, wherein the disease or condition is atherosclerosis.

23. (Original) The therapeutic composition of claim 20, wherein the disease or condition is a vascular disease selected from the group consisting of peripheral vascular disease, cerebrovascular disease and cardiovascular disease and any combination thereof.

24. (Original) A therapeutic protocol for prophylaxis or treatment of a disease or condition associated with endothelial cell dysfunction in a subject, the therapeutic protocol comprising:

providing a subject suffering from or thought to be at risk of suffering from a disease or condition associated with endothelial cell dysfunction; and

administering a small interfering RNA to the subject, wherein the small interfering RNA downregulates gene transcription associated with profilin-1 to prevent or treat the disease or condition.

25. (Original) The therapeutic protocol of claim 24, wherein the small interfering RNA is a synthetic small interfering RNA.

-5-

WEINGARTEN, SCHURGIN,  
GAGNERIS & LEBOVICI LLP  
TEL. (617) 542-2290  
FAX. (617) 451-0313

Application No. 10/589,687  
Filed: August 17, 2006  
TC Art Unit: 1647  
Confirmation No.: 9909

26. (Original) The therapeutic protocol of claim 24 or 25, wherein the small interfering RNA is delivered via a lentivirus.

27. (Original) The therapeutic protocol of claim 24 or 25, wherein the small interfering RNA is delivered to an artery selected from the group consisting of coronary, carotid, femoral and a combination thereof.

-6-

WEINGARTEN, SCHURGIN,  
GAGHERIN & LEOVICI LLP  
TEL. (617) 542-2290  
FAX. (617) 451-0313